Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 878-885

  Soulie P ^a   Ruffie P ^a   Trandafir, L ^a   Monnet, I ^a   Tardivon, A ^a   Terrier, P ^a   Cvitkovic, E ^a   Le Chevalier, T ^a   Armand, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MALIGNANT MESOTHELIOMA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0029868030     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.878     Document Type: Article

References (41)

1. Alberts AS, Falkson G, Goedhals L, et al: Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527-535, 1988
2. Law MR, Gregor A, Hodson ME, et al: Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients. Thorax 39:255-259, 1984
3. Mc Donald JC: Health implications of environmental exposure to asbestos. Environ Health Perspect 62:319-328, 1985
4. Rusch V, Saltz L, Venkatraman E, et al: A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12:1156-1163, 1994
5. Krarup-Hansen A, Hansen HH: Chemotherapy in malignant mesothelioma: A review. Cancer Chemother Pharmacol 28:319-330, 1991
6. Ruffie P: Mesothelioma chemotherapy. Eur Respir Rev 3:199-203, 1993
7. Planting A, Goey H, Verweij J: Phase II study of six weekly courses of high dose cisplatin (CDDP) in mesothelioma. Proc Am Assoc Clin Res 11:193, 1992 (abstr 1158)
8. Rebattu P, Merrouche Y, Blay JY, et al: Phase II study of very high dose cisplatin in the treatment of malignant mesothelioma. Eur Respir Rev 3:226-228, 1993
9. Levin L, Simon R, Hryniuk W, et al: Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose intensity analysis. J Natl Cancer Inst 27:1367-1372, 1991
10. Christmas TI, Manning LS, Garlepp MJ, et al: Effect of interferon-alpha2a on malignant mesothelioma. J Interferon Res 13:9-12, 1993
11. Ardizzoni A, Pennucci MC, Castagneto B, et al: Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 17:80-82, 1994
12. Bowman RV, Manning LS, Davis MR, et al: Chemosensitivity and cytokine sensitivity of malignant mesothelioma. Cancer Chemother Pharmacol 28:420-426, 1991
13. Hand A, Husgafvel-Pursiainen K, Ekman A, et al: Malignant mesothelioma: In vitro drug sensitivity testing on four human mesothelioma cell lines. Eur Respir Rev 3:229-230, 1993
14. Sklarin NT, Chahinian AP, Feuer EJ, et al: Augmentation of activity of cis-diamminedichloroplatinum (II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 48:64-67, 1988
15. Boutin C, Nussbaum E, Monnet I, et al: Intrapleural treatment with recombinant gamma interferon in early stage malignant pleural mesothelioma. Cancer 74:2460-2467, 1994
16. UICC: International Union against Cancer: TNM Classification of Malignant Tumours (ed 4, 2nd revision). Berlin, Germany, Springer Verlag, 1992, pp 81-83
17. Butchart EG, Aschroft T, Barnsley WC, et al: Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleural (experience with 29 patients). Thorax 31:15-24, 1976
18. Planting AST, Van der Burg MEL, De Boer-Dennert M, et al: Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer 68:789-792, 1993
19. Ruffie P, Feld R, Minkin S, et al: Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 7:1157-1168, 1989
20. Krarup-Hansen A: Phase II trials of malignant mesothelioma: A commentary and update. Lung Cancer 11:503-308, 1994
21. Vogelzang NJ, Weissman LB, Herndon JE II, et al: Trimetrexane in malignant mesothelioma: A Cancer and Leukemia Group B phase II study. J Clin Oncol 12:1436-1442, 1994
22. Belani CP, Herndon J, Vogelzang NJ, et al: Edatrexate for malignant mesothelioma: A Cancer and Leukemia Group B phase II study. Proc Am Soc Clin Oncol 13:329, 1994 (abstr 1087)
23. Vogelzang NJ, Herndon J, Clamon GH, et al: Paclitaxel (Taxol) for malignant mesothelioma (MM): A phase II study of the Cancer and Leukemia Group B (CALGB 9234). Proc Am Soc Clin Oncol 13:405, 1994 (abstr 1382)
24. Brown RW, Clark GM, Tandon AK, et al: Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 24:347-354, 1993
25. Chahinian AP, Antman K, Goutsou M, et al: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group. B. J Clin Oncol 11:1559-1565, 1993
26. Dabouis G, Le Mevel B, Corroller J: Treatment of diffuse pleural malignant mesothelioma by cis dichloro diammine platinum (CDDP) in nine patients. Cancer Chemother Pharmacol 5:209-210, 1981
27. Zidar BL, Green S, Pierce HI, et al: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 6:223-226, 1988
28. Mintzer DM, Kelsen D, Frimmer D, et al: Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69:711-712, 1985
29. Ozols RF, Ostchega Y, Myers CE, et al: High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 3:1246-1250, 1985
30. Wivel NA, Pitha PM: Interferon treatment of meth-A sarcoma cell effects on the malignant phenotype and expression of tumour specific and H2 antigens. Int J Cancer 30:649-654, 1982
31. Belardelli F, Gresser I, Maury C, et al: Antitumour effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukaemia cells. Int J Cancer 30:813-820, 1982
32. Balkwill FR, Mowshowitz S, Seilmain SS, et al: Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. Cancer Res 44:5249-5255, 1984
33. Balkwill FR: Antitumour effects of interferons in animals, in Finter WB, Oldham RK (eds): Interferon 4: In Vivo and Clinical Studies, vol 4. New York, NY, Elsevier, 1985, pp 23-45
34. Christmas TI, Manning LS, Davis MR, et al: HLA antigen expression and malignant mesothelioma. Am J Respir Cell Mol Biol 5:213-220, 1991
35. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 50:3473-3486, 1990
36. Quesada JR, Talpaz M, Rios A, et al: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 4:234-243, 1986
37. Walsh C, Speyer JL, Wernz J, et al: Phase I study of the combination of alpha-2 interferon and cisplatinum. J Biol Response Mod 8:11-15, 1989
38. Dhingra K, Talpaz M, Dhingra HM, et al: A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. Invest New Drugs 9:37-39, 1991
39. Vokes EE, Ratain MJ, Mick R, et al: Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 11:360-368, 1993
40. Ardizzoni A, Rosso R, Salvati F, et al: Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. Cancer 67:2984-2987, 1991
41. Trandafir L, Borel C, Ruffie P, et al: Combined systemic CDDP-interferon α (IFN) in advanced pleural malignant mesothelioma (MM). Proc Am Soc Clin Oncol 13:405, 1994 (abstr 1384)